Who are Retagliptin, Henagliflozein, metformin XR's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/retagliptin-henagliflozein-metformin-xr.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Retagliptin, Henagliflozein, metformin XR — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Retagliptin, Henagliflozein, metformin XR (Retagliptin, Henagliflozein, metformin XR) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor, GLP-1 receptor agonist, biguanide. Area: Diabetes.

phase 3 DPP-4 inhibitor, GLP-1 receptor agonist, biguanide DPP-4, GLP-1R Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Retagliptin, Henagliflozein, metformin XR (Retagliptin, Henagliflozein, metformin XR) — Jiangsu HengRui Medicine Co., Ltd.. Retagliptin, Henagliflozein, and metformin XR work together to lower blood sugar levels by enhancing insulin secretion and suppressing glucagon release, and also by decreasing glucose reabsorption in the kidneys.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Retagliptin, Henagliflozein, metformin XR TARGET	Retagliptin, Henagliflozein, metformin XR	Jiangsu HengRui Medicine Co., Ltd.	phase 3	DPP-4 inhibitor, GLP-1 receptor agonist, biguanide	DPP-4, GLP-1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor, GLP-1 receptor agonist, biguanide class)

Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Retagliptin, Henagliflozein, metformin XR — Competitive Intelligence Brief. https://druglandscape.com/ci/retagliptin-henagliflozein-metformin-xr. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab